Clinical · CREA-CLIN-01 · v2
Only one study in this corpus actually tested creatine for muscle function in a muscular dystrophy: a trial in children with facioscapulohumeral muscular dystrophy [1]. On its main pre-chosen measure of motor function, creatine did no better than placebo. Some other measures, such as how far children could walk in six minutes, moved in a favourable direction, but these differences were small enough that they could have happened by chance. The study was tiny and was designed mainly to test whether such a trial is even workable, not to prove the treatment works. Every other paper in the corpus tested a different treatment or a different disease and so does not speak to this claim. Taken together, the single relevant study leans against the claim but is too small to settle it either way.
Only one eligible trial [1] directly tests creatine for muscle function in a muscular dystrophy (pediatric FSHD). It was null on its primary endpoint, with "no clinically meaningful difference was seen between treatment groups as measured by the mean difference in MFM-32 (0.19, 95% confidence interval (CI) -0.71 to 1.08)" [1]. Secondary measures moved favourably but non-significantly, including "an improvement in 6-minute walk distance of 27.74 m (95% CI -1.41 to 56.88)" whose interval includes zero [1]. The trial was small, with "Thirteen children were enrolled" and "11 patients completed both trial treatment periods", and it "confirms the feasibility of conducting clinical trials in children with FSHD" [1]. No DMD, limb-girdle or adult-dystrophy creatine data are present, and the creatine paper in a non-dystrophy myopathy [9] and the gene-therapy, cell-therapy and other-supplement studies [3][4][5][6][7][8] do not test the claim. The contested point: The division is whether the favourable but non-significant secondary trends in [1] — notably the 6-minute walk distance of 27.74 m (95% CI -1.41 to 56.88) — count as any evidence of benefit, or whether, because every confidence interval spans zero, they are noise. The panel treats them as non-significant trends only, not as support for improvement.
All 9 papers behind this claim with their DOIs and what each does to it, the panel’s arbitration, the evidence gap map and the open research questions. Free, and sent to your inbox.
We’ll also send you other claims from Creatine, one at a time, and tell you when a release or a pivotal trial changes a grade. Unsubscribe by replying.
One reviewer's only job is to attack the finding. The challenges below were weighed before the grade was set.
The sole relevant trial [1] failed its pre-specified primary motor-function endpoint (MFM-32 difference 0.19, 95% CI -0.71 to 1.08 spans zero); the claim of improvement is contradicted by the direct evidence.
Severely underpowered: 13 enrolled, 11 completers, explicitly a feasibility study — insufficient to demonstrate efficacy either way.
Where it remains uncertain. Secondary measures such as "an improvement in 6-minute walk distance of 27.74 m (95% CI -1.41 to 56.88)" trended favourably, but every interval includes zero and the trial was an N=13 feasibility study [1].
Aleatory
With 13 enrolled and 11 completers [1], wide confidence intervals mean chance variation dominates; the favourable 6MWD trend (95% CI -1.41 to 56.88) could reflect random fluctuation rather than effect.
Epistemic
Only one eligible study [1], explicitly feasibility-scoped, so the corpus cannot establish whether a real motor-function effect exists or is simply undetected.
Inferential
Inferring improvement from non-significant secondary endpoints in [1] (6MWD interval includes zero) is not supported; direction of a confidence-interval-spanning estimate is not evidence of effect.
The load-bearing papers from a corpus of 9, each classified by what it does to the claim. Every DOI is taken from the corpus the claim was graded on.
Primary motor-function outcome was null, directly undercutting the claim that creatine improves muscle function in this muscular dystrophy.
“Although CrM had no effect on motor function as measured by the MFM-32 compared with placebo, there were trends toward improvement in the 6-minute walk distance and other secondary outcome measures.”
Panel auditInternal validity: medium · scope of inference: Children with FSHD (mean age 12.2 years) over two 12-week treatment periods, assessing motor function and secondary endurance/strength measures.Key limitations: very small sample · trends in secondaries not significant · single dystrophy subtype (FSHD) · pediatric only
1 of 9 papers shown. The full review lists all of them, with the panel’s arbitration →
Claims are graded at each quarterly release, and re-graded between releases only when a pivotal trial lands. Every change is a new version of the claim.
A lone, underpowered RCT that failed its primary motor-function endpoint cannot support an affirmative improvement claim, placing confidence in the Doubtful band.
Release 2026-q4 re-graded every claim from its corpus under protocol v0.19. An earlier release's grade is shown for the record; it came from an earlier protocol and is not a movement.
Assumptions that carry weight but are not themselves established.
The panel records the gap that would most move the claim, and the study that would close it.
Adequately powered FSHD trial. The only eligible study [1] was null on MFM-32 but feasibility-sized (N=13), so a true motor-function effect can be neither confirmed nor excluded. The panel rates this the highest-importance open gap for the claim, and names the study design that would close it: A larger randomized placebo-controlled trial of creatine in FSHD powered on MFM-32 and 6MWD, as [1] itself recommends, ideally stratifying by functional ability or MRI fat infiltration.
Open question: Does creatine improve motor function in facioscapulohumeral muscular dystrophy when tested in an adequately powered trial? Why it is still open: The only eligible trial [1] was null on its MFM-32 primary endpoint but was feasibility-scoped at N=13 with 11 completers, leaving efficacy undetermined.
Priors is a sceptical first reader, not peer review, and not medical advice.
Release 2026-q4 · graded 21 Oct 2026 · protocol v0.19